Skip to main content

BridgeBio Rolls Out New Academic Pacts to Advance Precision Oncology Programs

NEW YORK – BridgeBio on Tuesday announced precision oncology research collaborations with several academic institutions.

Specifically, the Palo Alto, California-based biotech has formed precision oncology-focused pacts with the University of California Davis; UC San Diego; Roswell Park Comprehensive Cancer Center; Oregon Health and Science University; and The Lundquist Institute for Biomedical Innovation at the Harbor-UC Los Angeles Medical Center.

The overarching focus of these new collaborations is to translate research on genetically driven cancers into precision treatments for patients. BridgeBio, which has a pipeline of more than 30 drug development programs for rare diseases and genetically validated cancers, will work closely with investigators at these academic institutions to identify early programs with the potential to benefit patients who have cancers with clear genetic drivers. The company will also provide expertise and support to these partner institutions to quickly advance promising research from the lab into clinical development. 

"The ability to tap into this network of expertise means greater visibility for our teams and enables a quicker path to the clinic for our most promising ideas and inventions in areas like genetics, bioinformatics, and molecular biology," Roswell Park CEO Candace Johnson said in a statement.